UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 3, 2012
Repros Therapeutics Inc.
(Exact name of registrant as specified in its charter)
Delaware |
001-15281 |
76-0233274 |
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
2408 Timberloch Place, Suite B-7 The Woodlands, Texas |
77380 |
| (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: (281) 719-3400
________________________________________________________________________________
(Former name or former address, if changed since last report)
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
||
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |
Item 8.01. Other Events.
On January 3, 2012 the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibit 99.1. Press release dated January 3, 2012
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Repros Therapeutics Inc.
(Registrant) |
||
| January 3, 2012
(Date) |
/s/ JOSEPH PODOLSKI
Joseph Podolski President and CEO |
| Exhibit Index | ||
| 99.1 | Press release dated January 3, 2012 | |
EXHIBIT 99.1
THE WOODLANDS, Texas, Jan. 3, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the Company has hired Donald Tredway as its Chief Medical Officer. Dr. Tredway joined Serono, Inc. in 2000 as a Medical Director in the Clinical Development Unit for Reproductive Health. In 2006 he was appointed Global Head of the Endocrinology and Reproductive Health Unit of Serono. Serono was acquired late 2006 by Merck KGA and Dr. Tredway was appointed Vice President and Global Head of the Fertility and Endocrinology GCDU for EMD Serono. He retired from EMD Serono July 2009 and has subsequently been acting as a regulatory and clinical development consultant to several pharmaceutical companies.
Dr. Tredway has previously reviewed the Repros programs and therefore it is anticipated he can make an immediate tactical impact on them.
Joseph Podolski, President and CEO of Repros Therapeutics, commented, "We are delighted to add a seasoned medical professional of Dr. Tredway's caliber. He has extensive experience in drug development in the specific areas of Repros' focus." He further noted, "I have been impressed with Dr. Tredway's scientific, clinical and regulatory acumen since I met him during discussions with his former company. I look forward to working with Don and I believe his addition will greatly add to our ability to push both of our programs towards timely NDA submission."
Regarding his joining Repros Therapeutics, Dr. Tredway commented, "I having been following Repros for a number of years and have been impressed with the company's handling of complex development difficulties. I am very positive regarding the continued development and registration of Androxal® and Proellex® and I am delighted to join the Repros team at this time."
About Repros Therapeutics Inc.
Repros Therapeutics focuses on the development of oral small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
The Repros Therapeutics Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7738
Any statements made by the Company that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including the ability to raise additional needed capital on a timely basis in order for it to continue to fund development of its Androxal® and Proellex® programs, have success in the clinical development of its technologies, the reliability of interim results to predict final study outcomes, and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov. Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please visit the Company's website at http://www.reprosrx.com.
CONTACT: Repros Therapeutics Inc.
Joseph Podolski (281) 719-3447
President and Chief Executive Officer